(Q39636381)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Victoria Saferding

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Peter Valent

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Michael Grusch

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Caroline Brünner-Kubath

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Waheed Shabbir

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Renate Wagner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Christian F Singer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Brigitte Marian

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Christoph C Zielinski

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Thomas W Grunt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

3 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

387-400

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21046231%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10549-010-1232-1

15 January 2020

exact match

0 references

cites work

Molecular approach to breast cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Novel tyrosine kinase inhibitors in the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

AKT plays a central role in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Getting back on track, or what to do when apoptosis is de-railed: recoupling oncogenes to the apoptotic machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

The development of HKI-272 and related compounds for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Akt activation by growth factors is a multiple-step process: the role of the PH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

A complex interplay between Akt, TSC2 and the two mTOR complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Redesigning kinase inhibitors to enhance specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

CI-1033, a pan-erbB tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Phosphatidylinositol-3-OH kinase as a direct target of Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1232-1